Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Background: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.
alirocumab、after、acute、cardiovascular、coronary、outcomes、syndrome
45
R541.405;R972.6;R4
2023-10-24(万方平台首次上网日期,不代表论文的发表时间)
共1页
1848